Protein biologics harnessing TSG‑6 biology to multi‑pathway modulate inflammation, protect tissues and promote repair. Lead therapeutic programs target Dry Eye Disease and wet age‑related macular degeneration, using subcutaneous delivery to avoid invasive intraocular injections.